Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) closed the day trading at $1.13 down -2.16% from the previous closing price of $1.15. In other words, the price has decreased by -$2.16 from its previous closing price. On the day, 1.2 million shares were traded. IRWD stock price reached its highest trading level at $1.15 during the session, while it also had its lowest trading level at $1.09.
Ratios:
For a better understanding of IRWD, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.98 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.13. For the most recent quarter (mrq), Quick Ratio is recorded 0.82 and its Current Ratio is at 0.82.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Gaskins Tammi L sold 1,316 shares for $0.84 per share. The transaction valued at 1,105 led to the insider holds 241,280 shares of the business.
John Minardo sold 7,754 shares of IRWD for $6,513 on Aug 11 ’25. The Chief Legal Officer now owns 400,378 shares after completing the transaction at $0.84 per share. On Aug 11 ’25, another insider, Martini Gregory S., who serves as the Chief Financial Officer of the company, sold 1,265 shares for $0.84 each. As a result, the insider received 1,063 and left with 182,545 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 187611632 and an Enterprise Value of 689367552. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.59. Its current Enterprise Value per Revenue stands at 2.234 whereas that against EBITDA is 7.359.
Stock Price History:
The Beta on a monthly basis for IRWD is 0.31, which has changed by -0.7230392 over the last 52 weeks, in comparison to a change of 0.18189907 over the same period for the S&P500. Over the past 52 weeks, IRWD has reached a high of $5.13, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 21.36%, while the 200-Day Moving Average is calculated to be -35.55%.
Shares Statistics:
Over the past 3-months, IRWD traded about 1.77M shares per day on average, while over the past 10 days, IRWD traded about 1255360 shares per day. A total of 162.43M shares are outstanding, with a floating share count of 156.37M. Insiders hold about 3.74% of the company’s shares, while institutions hold 90.49% stake in the company. Shares short for IRWD as of 1755216000 were 6071719 with a Short Ratio of 3.43, compared to 1752537600 on 6528581. Therefore, it implies a Short% of Shares Outstanding of 6071719 and a Short% of Float of 5.6700002.
Earnings Estimates
The dynamic stock of Ironwood Pharmaceuticals Inc (IRWD) is currently attracting attention from 1.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.11, with high estimates of $0.11 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.21 and $0.21 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.21, with 3.0 analysts recommending between $0.4 and $0.0.
Revenue Estimates
5 analysts predict $74.22M in revenue for the current quarter. It ranges from a high estimate of $83.4M to a low estimate of $68.4M. As of the current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $91.59MFor the next quarter, 5 analysts are estimating revenue of $76.4M. There is a high estimate of $84M for the next quarter, whereas the lowest estimate is $70M.
A total of 5 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $275.2M, while the lowest revenue estimate was $264M, resulting in an average revenue estimate of $272.3M. In the same quarter a year ago, actual revenue was $351.41MBased on 5 analysts’ estimates, the company’s revenue will be $258.84M in the next fiscal year. The high estimate is $285M and the low estimate is $225.8M.